Specific issues in the design and implementation of an efficacy trial for a Lyme disease vaccine

Clinical Infectious Diseases

Volumn 25, Issue 1 SUPPL., 1997, Pages

  Meurice, François ^b   Parenti, Dennis ^b   Fu, Darrick ^b   Krause, David S ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; OUTER MEMBRANE PROTEIN; PLACEBO; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; BORRELIA BURGDORFERI; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; LYME DISEASE; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; VACCINATION;

EID: 0030787543     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/516167     Document Type: Conference Paper

References (18)

1. Steere AC. Lyme disease. N Engl J Med 1989;321:586-96.
2. Steere AC, Malawista SE, Snydman DR, et al. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three Connecticut communities. Arthritis Rheum 1977;20:7-17.
3. Fikrig E, Barthold SW, Marcantonio N, Deponte K, Kanter FS, Flavell RA. Roles of OspA, OspB, and flagellin in protective immunity to Lyme borreliosis in laboratory mice. Infect Immun 1992;60:657-61.
4. Fikrig E, Telford SR III, Barthold SW, Kantor FS, Spielman A, Flavell RA. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. Proc Natl Acad Sci USA 1992;89:5418-21.
5. Rahn DW, Malawista SE. Lyme disease: recommendations for diagnosis and treatment. Ann Intern Med 1991; 114:472-81.
6. Telford SR III, Kantor FS, Lobet Y, et al. Efficacy of human Lyme disease vaccine formulations in a mouse model. J Infect Dis 1995;171:1368-70.
7. Van Hoecke C, Fu D, de Grave D, Lebacq E. Evaluation of a lipoprotein OspA vaccine administered following a 0, l, 2 month primary vaccination course with a booster at month 12 [abstract no G81]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995:172.
8. Shih CM, Spielman A, Telford SR III. Mode of action of protective immunity to Lyme disease spirochetes. Am J Trop Med Hyg 1995;52:72-4.
9. Fikrig E, Telford SR III, Wallich R, et al. Vaccination against Lyme disease caused by diverse Borrelia burgdorferi. J Exp Med 1995;181:215-21.
10. Telford S, Krause P, Meurice F, et al. Safety and immunogenicity of a candidate Lyme disease vaccine in residents of endemic New England sites [abstract no G31]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995: 164.
11. Schoen RT, Meurice F, Brunet CM, et al. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease. J Infect Dis 1995;172:1324-9.
12. Centers for Disease Control and Prevention. Lyme disease - United States, 1991-1992. MMWR Morb Mortal Wkly Rep 1993;42:345-8.
13. Centers for Disease Control and Prevention. Lyme disease - United States, 1994. MMWR Morb Mortal Wkly Rep 1995;44:459-62.
14. Centers for Disease Control and Prevention. Lyme disease - United States, 1993. MMWR Morb Mortal Wkly Rep 1994;43:564-72.
15. Connecticut Department of Public Health and Addiction Services. Lyme disease update. Connecticut Epidemiologist 1993; 13:9-10.
16. Feder HM Jr, Gerber MA, Cartter ML, Sikand V, Krause PJ. Prospective assessment of Lyme disease in a school-aged population in Connecticut. J Infect Dis 1995;171:1371-4.
17. Spielman A, Wilson ML, Levine JF, Piesman J. Ecology of Ixodes dammini-borne human babesiosis and Lyme disease. Annu Rev Entomol 1985;30:439-60.
18. Centers for Disease Control and Prevention. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme disease. MMWR Morb Mortal Wkly Rep 1995;44:590-1.